Poster Presentations: Wednesday, October 26, 2011 |

Bone Mineral Density Changes in Male Patients With Chronic Obstructive Pulmonary Disease: Clinical and Biochemical Variables in Correlation With Glucocorticoids Use FREE TO VIEW

Sherif Alsayed, MD
Author and Funding Information

New Jeddah Clinic Hospital, Jeddah, Saudi Arabia

Chest. 2011;140(4_MeetingAbstracts):520A. doi:10.1378/chest.1112192
Text Size: A A A
Published online


PURPOSE: Few data are available in correlation between bone mass density (BMD) and men with COPD This study was designed to investigate the prevalence of osteoporosis in men with COPD. with special regards to the role of glucocorticoids (GCs) use in these patients

METHODS: The study included 56 male patients with documented COPD for at least two years, their age ranged 24-66 years. Subjects were divided into 3 groups: group 1. consisted of 18 patients, who were oral GCs users, group 2. consisted of 18 patients who were inhaled GCs users and group 3. consisted of 20 patients, never GCs users (this group was considered as the control group). All subjects underwent measurement of BMD. pulmonary function tests (PFTs) and a number of biochemical markers of bone metabolism. The associations between BMD. PFTs. GCs use. biochemical markers and clinical variables were analyzed.

RESULTS: Patients included group 1 had the lowest BMD at any site (p< 0.0001). group 2 patients had over all bone mass loss, that was indistinguishable from those who were received oral GCs. group 3 patients had less bone mass reduction than the other two groups. Of the clinical and biochemical markers measured. N-telopeptide was significantly correlated with bone mass (P<0.01), but there was no correlation with other markers. The lowest mean of FEV1 (Forced Expiratory Volume in one second) was observed in group 1 patients. BMI (Body Mass Index) was weakly correlated with bone mass in the 3 studied groups

CONCLUSIONS: Bone mass loss is a common problem in male patients with COPD. while the use of oral GCs increase the frequency of osteoporosis, inhaled GCs therapy offered no protection from bone loss.

CLINICAL IMPLICATIONS: COPD patients who had never treated with GCs had also a substantial risk for osteoporosis. We advocate early screening and preventive intervention.

DISCLOSURE: The following authors have nothing to disclose: Sherif Alsayed

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Declining Bone Mass in Men With Chronic Pulmonary Disease*: Contribution of Glucocorticoid Treatment, Body Mass Index, and Gonadal Function
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543